Welcome to our dedicated page for Edgewise Therapeutics SEC filings (Ticker: EWTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Edgewise Therapeutics, Inc. (NASDAQ: EWTX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Edgewise is a clinical-stage biopharmaceutical company developing therapeutics for muscular dystrophies and serious cardiac conditions, and its filings offer detailed information on clinical progress, financial results, and corporate governance.
Investors can review current reports on Form 8-K that Edgewise files to announce material events, such as clinical data updates for sevasemten in Becker and Duchenne muscular dystrophies, progress in the EDG-7500 CIRRUS-HCM Phase 2 trial in hypertrophic cardiomyopathy, and initiation of Phase 1 studies for EDG-15400 in heart failure. Other 8-K filings describe financial results for specific quarters, appointments of new directors and executive officers, and equity-based compensation arrangements, including inducement grants under Nasdaq Listing Rule 5635(c)(4).
Through this page, users can also locate references to annual and quarterly reports (Forms 10-K and 10-Q) and related exhibits, where Edgewise discusses risk factors, liquidity, research and development expenses, and dependence on key product candidates such as sevasemten and EDG-7500. Disclosures frequently highlight that the company is clinical-stage, has not generated product revenue, and faces the typical uncertainties of drug development and regulatory approval.
Stock Titan enhances these filings with AI-powered summaries that explain the key points of lengthy documents, helping readers quickly understand clinical, financial, and governance information. Users can also track insider and equity-related disclosures reported in 8-K exhibits and other filings to see how leadership and directors are compensated and how the company structures its incentive plans.
Edgewise Therapeutics, Inc. received an Amendment No. 1 to a Schedule 13G filed by Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker and Felix J. Baker reporting aggregate beneficial ownership of 7,305,940 shares of common stock, representing 6.9% of the 105,200,221 shares outstanding used for the calculation. The filing states the Adviser has sole investment and voting power over those shares through management agreements with two funds, Baker Brothers Life Sciences, L.P. and 667, L.P., which directly hold 6,762,577 and 543,363 shares respectively. The disclosure is presented as an amendment and certifies the securities are held in the ordinary course of business and not to change or influence control of the issuer.
Janus Henderson Group plc filed a Schedule 13G/A reporting beneficial ownership of Edgewise Therapeutics common stock. The filing lists an aggregate holding of 5,503,349 shares, representing 5.2% of the class, with shared voting and shared dispositive power. The filing also states that certain indirect subsidiaries (JHIUS, JHIUKL and JHIAIFML) are registered investment advisers to managed portfolios, and Item 4 separately indicates JHIUS may be deemed to beneficially own 5,437,423 shares (also shown as 5.2%). The statement includes a certification that the shares are held in the ordinary course of business and not to influence control. The filing is signed by Kristin Mariani on 08/14/2025.
Edgewise Therapeutics (Nasdaq:EWTX) filed an 8-K furnishing upbeat interim data on sevasemten for Becker and Duchenne muscular dystrophies and summarizing recent FDA guidance.
- MESA extension (n = 85): 0.8-point NSAA improvement over 18 months, 3-year disease stabilization and 99 % rollover from prior studies.
- Placebo switchers gained 0.2 NSAA points.
- Safety remains favorable after up to three years.
- FDA confirmed NSAA as a meaningful endpoint and indicated the ongoing GRAND CANYON study (topline Q4 2026) could be a single pivotal trial for Becker registration.
- Duchenne Phase 2 LYNX & FOX: Well-tolerated across doses; 10 mg selected for Phase 3 after functional and biomarker benefits.
Management plans a Phase 3 design meeting with FDA in Q4 2025 and expects pivotal Duchenne enrollment in 2026. No financial metrics were disclosed.
Form 4 Filing Details: Laura Brege, Director of Edgewise Therapeutics (EWTX), received a stock option grant on June 16, 2025. The transaction involves the following key details:
- Granted 30,000 stock options to purchase common stock
- Exercise price set at $14.68 per share
- Options will vest fully on the earlier of: - June 16, 2026 - Day before 2026 annual stockholder meeting
- Options expire on June 16, 2035
This grant represents standard director compensation and aligns the director's interests with shareholders through long-term equity incentives. The filing was submitted by John R. Moore as attorney-in-fact for Laura Brege on June 18, 2025.
Edgewise Therapeutics (EWTX) director Badreddin Edris received a stock option grant for 30,000 shares of common stock on June 16, 2025. The options were granted with an exercise price of $14.68 per share.
Key terms of the stock option grant:
- Exercise price: $14.68 per share
- Vesting schedule: 100% vesting on the earlier of June 16, 2026, or the day before the 2026 annual stockholder meeting
- Expiration date: June 16, 2035
- Ownership form: Direct
The Form 4 was filed by attorney-in-fact John R. Moore on behalf of Badreddin Edris on June 18, 2025, within the required two-business-day filing window following the transaction.
Edgewise Therapeutics director Jonathan C. Fox received a stock option grant on June 16, 2025, as reported in this Form 4 filing. The derivative securities transaction details include:
- Grant of 30,000 stock options to purchase common stock
- Exercise price set at $14.68 per share
- Options will vest fully on the earlier of June 16, 2026 or the day before the 2026 annual stockholder meeting
- Options expire on June 16, 2035
This grant represents a standard annual director compensation award. The filing was signed by John R. Moore as attorney-in-fact for Fox on June 18, 2025. The reporting person maintains direct ownership of these derivative securities.
Edgewise Therapeutics Director Arlene Morris received a stock option grant on June 16, 2025, representing a significant insider transaction. The key details of this Form 4 filing include:
- Granted 30,000 stock options to purchase common stock
- Exercise price set at $14.68 per share
- Options will vest fully on the earlier of June 16, 2026 or the day before the 2026 annual stockholder meeting
- Options expire on June 16, 2035
This grant appears to be part of the company's director compensation program. The one-year cliff vesting schedule aligns with typical board member equity compensation structures. The filing was completed by Attorney-in-Fact John R. Moore on June 18, 2025.
FAQ
What is the current stock price of Edgewise Therapeutics (EWTX)?
What is the market cap of Edgewise Therapeutics (EWTX)?
